IL-6 Revisited: From Rheumatoid Arthritis to CAR T Cell Therapy and COVID-19

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884

Clinical characteristics of coronavirus disease 2019 in China

Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263

Dexamethasone in Hospitalized Patients with Covid-19

The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477

COVID-19: consider cytokine storm syndromes and immunosuppression

Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30628-0 · Cited by 9,664

Toll-like receptor signalling

Akira, S., & Takeda, K. (2004) · Nature reviews. Immunology · doi:10.1038/nri1391 · Cited by 8,312

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China

Wu, C., Chen, X., Cai, Y., Xia, J., Zhou, X., Xu, S., Huang, H., Zhang, L., Zhou, X., Du, C., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.0994 · Cited by 8,249

Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells

Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992

Endothelial cell infection and endotheliitis in COVID-19

Varga, Z., Flammer, A. J., Steiger, P., Haberecker, M., Andermatt, R., Zinkernagel, A. S., Mehra, M. R., Schuepbach, R. A., Ruschitzka, F., & Moch, H. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30937-5 · Cited by 6,358

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413

IL‐6 in inflammation, immunity, and disease

Tanaka, T., Narazaki, M., & Kishimoto, T. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016295 · Cited by 5,046

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509

Interleukin-6 and the acute phase response

Heinrich, P. C., Castell, J. V., & Andus, T. (1990) · Biochemical Journal · doi:10.1042/bj2650621 · Cited by 2,734

Effective treatment of severe COVID-19 patients with tocilizumab

Xu, X., Han, M., Li, T., Sun, W., Wang, D., Fu, B., Zhou, Y., Zheng, X., Yang, Y., Li, X., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2005615117 · Cited by 2,670

IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin

Nemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B. K., & Ganz, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420945 · Cited by 2,650

IL-6 as a keystone cytokine in health and disease

Hunter, C. A., & Jones, S. A. (2015) · Nature Immunology · doi:10.1038/ni.3153 · Cited by 2,511

The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis.

Fishman, D., Faulds, G., Jeffery, R., Mohamed-Ali, V, Yudkin, J. S., Humphries, S., & Woo, P. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2629 · Cited by 2,243

The spectrum of neuromyelitis optica

Wingerchuk, D. M., Lennon, V. A., Lucchinetti, C. F., Pittock, S. J., & Weinshenker, B. G. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70216-8 · Cited by 2,182

Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin

Hirano, T., Yasukawa, K., Harada, H., Taga, T., Watanabe, Y., Matsuda, T., Kashiwamura, S.-I., Nakajima, K., Koyama, K., Iwamatsu, A., et al. (1986) · Nature · doi:10.1038/324073a0 · Cited by 2,139

Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway

HEINRICH, P. C., BEHRMANN, I., MÜLLER-NEWEN, G., SCHAPER, F., & GRAEVE, L. (1998) · Biochemical Journal · doi:10.1042/bj3340297 · Cited by 2,130

The biology of interleukin-6

Kishimoto, T. (1989) · Blood · doi:10.1182/blood.v74.1.1.bloodjournal7411 · Cited by 2,068

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063

Disseminated Intravascular Coagulation

Levi, M. M., & Cate, H. T. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908193410807 · Cited by 2,035

Juvenile idiopathic arthritis

Ravelli, A., & Martini, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60363-8 · Cited by 2,017

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

Abani, O., Abbas, A., Abbas, F., Abbas, M., Abbasi, S., Abbass, H., Abbott, A., Abdallah, N., Abdelaziz, A., Abdelfattah, M., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00676-0 · Cited by 1,983

Interleukin-6 receptor antagonists in critically ill patients with Covid-19.

The REMAP-CAP Investigators (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100433 · Cited by 1,962

Cytokine release syndrome in severe COVID-19

Moore, J. B., & June, C. H. (2020) · Science · doi:10.1126/science.abb8925 · Cited by 1,912

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

Porter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729

IL‐6: Regulator of Treg/Th17 balance

Kimura, A., & Kishimoto, T. (2010) · European Journal of Immunology · doi:10.1002/eji.201040391 · Cited by 1,654

Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas

Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., et al. (1988) · Nature · doi:10.1038/332083a0 · Cited by 1,633

Liver Failure and Defective Hepatocyte Regeneration in Interleukin-6-Deficient Mice

Cressman, D. E., Greenbaum, L. E., DeAngelis, R. A., Ciliberto, G., Furth, E. E., Poli, V., & Taub, R. (1996) · Science · doi:10.1126/science.274.5291.1379 · Cited by 1,538

Interleukin-6 and chronic inflammation

Gabay, C. (2006) · Arthritis Research & Therapy · doi:10.1186/ar1917 · Cited by 1,468

A nuclear factor for IL‐6 expression (NF‐IL6) is a member of a C/EBP family.

Akira, S., Isshiki, H., Sugita, T., Tanabe, O., Kinoshita, S. M., Nishio, Y., Nakajima, T., Hirano, T., & Kishimoto, T. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb08316.x · Cited by 1,450

Increased Osteoclast Development After Estrogen Loss: Mediation by Interleukin-6

Jilka, R. L., Hangoc, G., Girasole, G., Passeri, G., Williams, D. C., Abrams, J. S., Boyce, B. F., Broxmeyer, H. E., & Manolagas, S. C. (1992) · Science · doi:10.1126/science.1621100 · Cited by 1,440

Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells

Norelli, M., Camisa, B., Barbiera, G., Falcone, L., Purevdorj, A., Genua, M., Sanvito, F., Ponzoni, M., Doglioni, C., Cristofori, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0036-4 · Cited by 1,406

Interleukin-6 in Biology and Medicine

Akira, S., Taga, T., & Kishimoto, T. (1993) · Advances in immunology · doi:10.1016/s0065-2776(08)60532-5 · Cited by 1,402

Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells

Gust, J., Hay, K. A., Hanafi, L.-A., Li, D., Myerson, D., Gonzalez-Cuyar, L. F., Yeung, C., Liles, W. C., Wurfel, M., Lopez, J. A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0698 · Cited by 1,400

Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130

Taga, T., Hibi, M., Hirata, Y., Yamasaki, K., Yasukawa, K., Matsuda, T., Hirano, T., & Kishimoto, T. (1989) · Cell · doi:10.1016/0092-8674(89)90438-8 · Cited by 1,396

Trial of tocilizumab in giant-cell arteritis

Stone, J. H., Tuckwell, K., Dimonaco, S., Klearman, M., Aringer, M., Blockmans, D., Brouwer, E., Cid, M. C., Dasgupta, B., Rech, J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613849 · Cited by 1,386

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia

Salama, C., Han, J., Yau, L., Reiss, W. G., Krämer, B., Neidhart, J. D., Criner, G. J., Kaplan‐Lewis, E., Baden, R. P., Pandit, L. M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2030340 · Cited by 1,306

CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade

Giavridis, T., van der Stegen, S. J. C., Eyquem, J., Hamieh, M., Piersigilli, A., & Sadelain, M. (2018) · Nature Medicine · doi:10.1038/s41591-018-0041-7 · Cited by 1,272

MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions

Gerszten, R. E., García-Zepeda, E. A., Lim, Y.-C., Yoshida, M., Ding, H. A., Gimbrone, M. A., Luster, A. D., Luscinskas, F. W., & Rosenzweig, A. (1999) · Nature · doi:10.1038/19546 · Cited by 1,263

Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study

Goshua, G., Pine, A. B., Meizlish, M. L., Chang, C., Zhang, H., Bahel, P., Baluha, A., Bar, N., Bona, R., Burns, A. J., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30216-7 · Cited by 1,147

Role of IL-6 and Its Soluble Receptor in Induction of Chemokines and Leukocyte Recruitment

Romano, M., Sironi, M., Toniatti, C., Polentarutti, N., Fruscella, P., Ghezzi, P., Faggioni, R., Luini, W., van Hinsbergh, V. W. M., Sozzani, S., et al. (1997) · Immunity · doi:10.1016/s1074-7613(00)80334-9 · Cited by 1,124

Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer

Jones, S. A., & Jenkins, B. J. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0066-7 · Cited by 1,102

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia

Teachey, D. T., Lacey, S. F., Shaw, P. A., Melenhorst, J. J., Maude, S. L., Frey, N., Pequignot, E., Gonzalez, V. E., Chen, F., Finklestein, J., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0040 · Cited by 1,102

Identification of a T cell-derived b cell growth factor distinct from interleukin 2.

Howard, M., Farrar, J., Hilfiker, M. L., Johnson, B., Takatsu, K., Hamaoka, T., & Paul, W. E. (1982) · The Journal of Experimental Medicine · doi:10.1084/jem.155.3.914 · Cited by 1,099

Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-κB and AP-1

Delerive, P., De Bosscher, K., Besnard, S., Vanden Berghe, W., Peters, J. M., Gonzalez, F. J., Fruchart, J.-C., Tedgui, A., Haegeman, G., & Staels, B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.45.32048 · Cited by 1,089

Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome

Minegishi, Y., Saitō, M., Tsuchiya, S., Tsuge, I., Takada, H., Hara, T., Kawamura, N., Ariga, T., Pašić, S., Stojković, O., et al. (2007) · Nature · doi:10.1038/nature06096 · Cited by 1,075

Cloning and Expression of the Human Interleukin-6 (BSF-2/IFNβ 2) Receptor

Yamasaki, K., Taga, T., Hirata, Y., Yawata, H., Kawanishi, Y., Seed, B., Taniguchi, T., Hirano, T., & Kishimoto, T. (1988) · Science · doi:10.1126/science.3136546 · Cited by 1,059

Interleukin 6 Induces the Expression of Vascular Endothelial Growth Factor

Cohen, T., Nahari, D., Weiss-Cerem, L., Neufeld, G., & Levi, B.-Z. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.2.736 · Cited by 1,042

INTERLEUKIN-6: From Basic Science to Medicine—40 Years in Immunology

Kishimoto, T. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115806 · Cited by 1,040

Structure and function of a new STAT-induced STAT inhibitor

Naka, T., Narazaki, M., Hirata, M., Matsumoto, T., Minamoto, S., Aono, A., Nishimoto, N., Kajita, T., Taga, T., Yoshizaki, K., et al. (1997) · Nature · doi:10.1038/43219 · Cited by 1,040

Molecular cloning and expression of an IL-6 signal transducer, gp130

Hibi, M., Murakami, M., Saito, M., Hirano, T., Taga, T., & Kishimoto, T. (1990) · Cell · doi:10.1016/0092-8674(90)90411-7 · Cited by 1,039

Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway

Akira, S., Nishio, Y., Inoue, M., Wang, X.-J., We, S., Matsusaka, T., Yoshida, K., Sudo, T., Naruto, M., & Kishimoto, T. (1994) · Cell · doi:10.1016/0092-8674(94)90235-6 · Cited by 1,019

DAMPening Inflammation by Modulating TLR Signalling

Piccinini, A. M., & Midwood, K. S. (2010) · Mediators of Inflammation · doi:10.1155/2010/672395 · Cited by 1,008

Choice of STATs and Other Substrates Specified by Modular Tyrosine-Based Motifs in Cytokine Receptors

Stahl, N., Farruggella, T. J., Boulton, T. G., Zhong, Z., Darnell, J. E., & Yancopoulos, G. D. (1995) · Science · doi:10.1126/science.7871433 · Cited by 979

The procoagulant pattern of patients with COVID‐19 acute respiratory distress syndrome

Ranucci, M., Ballotta, A., Dedda, U. D., Baryshnikova, E., Poli, M., Resta, M. V., Falco, M., Albano, G., & Menicanti, L. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14854 · Cited by 978

Tocilizumab in patients with severe COVID-19: a retrospective cohort study

Guaraldi, G., Meschiari, M., Cozzi-Lepri, A., Milic, J., Tonelli, R., Menozzi, M., Franceschini, E., Cuomo, G., Orlando, G., Borghi, V., et al. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30173-9 · Cited by 939

Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease

Yoshizaki, K., Matsuda, T., Nishimoto, N., Kuritani, T., Taeho, L., Aozasa, K., Nakahata, T., Kawai, H., Tagoh, H., & Komori, T. (1989) · Blood · doi:10.1182/blood.v74.4.1360.1360 · Cited by 928

Targeting Interleukin-6 Signaling in Clinic

Kang, S., Tanaka, T., Narazaki, M., & Kishimoto, T. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.026 · Cited by 904

Impaired response to interferon-α/β and lethal viral disease in human STAT1 deficiency

Boisson‐Dupuis, S., Jouanguy, E., Al-Hajjar, S. H., Fieschi, C., Al-Mohsen, I. Z., Aljumaah, S., Yang, K., Chapgier, A. L. A., Eidenschenk, C., Eid, P., et al. (2003) · Nature Genetics · doi:10.1038/ng1097 · Cited by 814

IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation

Kaplanski, G. (2003) · Trends in Immunology · doi:10.1016/s1471-4906(02)00013-3 · Cited by 811

Hyper-IgE Syndrome with Recurrent Infections — An Autosomal Dominant Multisystem Disorder

Grimbacher, B., Holland, S. M., Gallin, J. I., Greenberg, F., Hill, S. C., Malech, H. L., Miller, J., O’Connell, A. C., & Puck, J. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400904 · Cited by 801

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

Jones, G., Sebba, A., Gu, J., Lowenstein, M. B., Calvo, A., Gomez-Reino, J. J., Siri, D. A., Tomšič, M., Alecock, E., Woodworth, T., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.105197 · Cited by 797

Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate

Maini, R. N., Taylor, P. C., Szechinski, J., Pavelka, K., Bröll, J., Balint, G., Emery, P., Raemen, F., Petersen, J., Smolen, J., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22033 · Cited by 790

Treatment of rheumatoid arthritis with humanized anti–interleukin‐6 receptor antibody: A multicenter, double‐blind, placebo‐controlled trial

Nishimoto, N., Yoshizaki, K., Miyasaka, N., Yamamoto, K., Kawai, S., Takeuchi, T., Hashimoto, J., Azuma, J., & Kishimoto, T. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20303 · Cited by 786

Humanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman disease

Nishimoto, N., Kanakura, Y., Aozasa, K., Johkoh, T., Nakamura, M., Nakano, S., Nakano, N., Ikeda, Y., Sasaki, T., Nishioka, K., et al. (2005) · Blood · doi:10.1182/blood-2004-12-4602 · Cited by 754

Interleukin‐6 deficient mice are protected from bone loss caused by estrogen depletion.

Poli, V., Balena, R. F., Fattori, E., Markatos, A., Yamamoto, M., Tanaka, H., Ciliberto, G., Rodan, G. A., & Costantini, F. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06368.x · Cited by 745

Immunotherapeutic Implications of Il-6 Blockade for Cytokine Storm

Tanaka, T., Narazaki, M., & Kishimoto, T. (2016) · Immunotherapy · doi:10.2217/imt-2016-0020 · Cited by 719

Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells

Esser, S., Lampugnani, M. G., Corada, M., Dejana, E., & Risau, W. (1998) · Journal of Cell Science · doi:10.1242/jcs.111.13.1853 · Cited by 715

Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis

The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Domingo, P., Mur, I., Mateo, G. M., Gutierrez, M. D. M., Pomar, V., de Benito, N., Corbacho, N., Herrera, S., Millan, L., et al. (2021) · JAMA · doi:10.1001/jama.2021.11330 · Cited by 678

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

Gabay, C., Emery, P., van Vollenhoven, R., Dikranian, A., Alten, R., Pavelka, K., Klearman, M., Musselman, D., Agarwal, S., Green, J., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60250-0 · Cited by 672

Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder

Yamamura, T., Kleiter, I., Fujihara, K., Palace, J. A., Greenberg, B. M., Zakrzewska‐Pniewska, B., Patti, F., Tsai, C., Saiz, A., Yamazaki, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901747 · Cited by 663

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8)

Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., & Engert, A. (1999) · Blood · doi:10.1182/blood.v94.7.2217.419k02_2217_2224 · Cited by 657

Zc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay

Matsushita, K., Takeuchi, O., Standley, D. M., Kumagai, Y., Kawagoe, T., Miyake, T., Satoh, T., Kato, H., Tsujimura, T., Nakamura, H., et al. (2009) · Nature · doi:10.1038/nature07924 · Cited by 649

Interleukin-6: designing specific therapeutics for a complex cytokine

Garbers, C., Heink, S., Korn, T., & Rose-John, S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.45 · Cited by 643

Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy

Teachey, D. T., Rheingold, S. R., Maude, S. L., Zugmaier, G., Barrett, D. M., Seif, A. E., Nichols, K. E., Suppa, E. K., Kalos, M., Berg, R. A., et al. (2013) · Blood · doi:10.1182/blood-2013-02-485623 · Cited by 613

The origins, function, and regulation of T follicular helper cells

Ma, C. S., Deenick, E. K., Batten, M., & Tangye, S. G. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20120994 · Cited by 577

Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial

Choy, E. H. S., Isenberg, D. A., Garrood, T., Farrow, S., Ioannou, Y., Bird, H., Cheung, N., Williams, B., Hazleman, B., Price, R., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10623 · Cited by 526

Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial

Traboulsee, A., Greenberg, B. M., Bennett, J. L., Szczechowski, L., Fox, E., Shkrobot, S., Yamamura, T., Terada, Y., Kawata, Y., Wright, P., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30078-8 · Cited by 513

Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis.

Guerne, P. A., Zuraw, B. L., Vaughan, J. H., Carson, D. A., & Lotz, M. (1989) · Journal of Clinical Investigation · doi:10.1172/jci113921 · Cited by 512

Tocilizumab for Treatment of Mechanically Ventilated Patients With COVID-19

Somers, E. C., Eschenauer, G. A., Troost, J. P., Golob, J. L., Gandhi, T. N., Wang, L., Zhou, N., Petty, L. A., Baang, J. H., Dillman, N. O., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa954 · Cited by 505

Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica

Chihara, N., Aranami, T., Sato, W., Miyazaki, Y., Miyake, S., Okamoto, T., Ogawa, M., Toda, T., & Yamamura, T. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017385108 · Cited by 476

HTLV-I Tax Induces Cellular Proteins that Activate the κB Element in the IL-2 Receptor α Gene

Ballard, D. W., Böhnlein, E., Lowenthal, J. W., Wano, Y., Franza, B. R., & Greene, W. C. (1988) · Science · doi:10.1126/science.2843985 · Cited by 474

Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages

Liao, W., Lin, J.-X., Wang, L., Li, P., & Leonard, W. J. (2011) · Nature Immunology · doi:10.1038/ni.2030 · Cited by 474

Bacterial lipopolysaccharide and inflammatory mediators augment IL-6 secretion by human endothelial cells.

Jirik, F. R., Podor, T. J., Hirano, T., Kishimoto, T., Loskutoff, D. J., Carson, D. A., & Lotz, M. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.142.1.144 · Cited by 458

A panoramic review of IL-6: Structure, pathophysiological roles and inhibitors

Kaur, S., Bansal, Y., Kumar, R., & Bansal, G. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115327 · Cited by 454

Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy

Nishimoto, N., Sasai, M., Shima, Y., Nakagawa, M., Matsumoto, T., Shirai, T., Kishimoto, T., & Yoshizaki, K. (2000) · Blood · doi:10.1182/blood.v95.1.56.001k13_56_61 · Cited by 445

Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130

Narazaki, M., Yasukawa, K., Saito, T., Ohsugi, Y., Fukui, H., Koishihara, Y., Yancopoulos, G. D., Taga, T., & Kishimoto, T. (1993) · Blood · doi:10.1182/blood.v82.4.1120.bloodjournal8241120 · Cited by 431

Aryl hydrocarbon receptor in combination with Stat1 regulates LPS-induced inflammatory responses

Kimura, A., Naka, T., Nakahama, T., Chinen, I., Masuda, K., Nohara, K., Fujii‐Kuriyama, Y., & Kishimoto, T. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20090560 · Cited by 426

AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance

Jarius, S., & Wildemann, B. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.72 · Cited by 424

Human papillomavirus infection and non-melanoma skin cancer in immunosuppressed and immunocompetent individuals

Harwood, C. A., Surentheran, T., McGregor, J., Spink, P. J., Leigh, I. M., Breuer, J., & Proby, C. M. (2000) · Journal of Medical Virology · doi:10.1002/1096-9071(200007)61:3 · Cited by 420

IL-6 and NF-IL6 in acute-phase response and viral infection

Akira, S., & Kishimoto†, T. (1992) · Immunological Reviews · doi:10.1111/j.1600-065x.1992.tb01407.x · Cited by 411

Interleukin 6 plays a key role in the development of antigen-induced arthritis

Ohshima, S., Saeki, Y., Mima, T., Sasai, M., Nishioka, K., Nomura, S., Kopf, M., Katada, Y., Tanaka, T., Suemura, M., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8222 · Cited by 406

Anti–interleukin‐6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis

Nakahara, H., Song, J., Sugimoto, M., Hagihara, K., Kishimoto, T., Yoshizaki, K., & Nishimoto, N. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11143 · Cited by 403

Regnase-1 and Roquin Regulate a Common Element in Inflammatory mRNAs by Spatiotemporally Distinct Mechanisms

Mino, T., Murakawa, Y., Fukao, A., Vandenbon, A., Wessels, H.-H., Ori, D., Uehata, T., Tartey, S., Akira, S., Suzuki, Y., et al. (2015) · Cell · doi:10.1016/j.cell.2015.04.029 · Cited by 390

Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells

Heink, S., Yogev, N., Garbers, C., Herwerth, M., Aly, L., Gasperi, C., Husterer, V., Croxford, A. L., Möller-Hackbarth, K., Bartsch, H. S., et al. (2017) · Nature Immunology · doi:10.1038/ni.3632 · Cited by 386

Identification of IL6R and chromosome 11q13.5 as risk loci for asthma

Ferreira, M. A., Matheson, M. C., Duffy, D. L., Marks, G. B., Hui, J., Le Souëf, P., Danoy, P., Baltic, S., Nyholt, D. R., Jenkins, M., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60874-x · Cited by 381

Therapeutic efficacy of humanized recombinant anti–interleukin‐6 receptor antibody in children with systemic‐onset juvenile idiopathic arthritis

Yokota, S., Miyamae, T., Imagawa, T., Iwata, N., Katakura, S., Mori, M., Woo, P. M., Nishimoto, N., Yoshizaki, K., & Kishimoto, T. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20944 · Cited by 370

Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome

Kreins, A. Y., Ciancanelli, M. J., Okada, S., Kong, X., Ramirez‐Alejo, N., Kılıç, S. Ş., Baghdadi, J. E., Nonoyama, S., Mahdaviani, S. A., Ailal, F., et al. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20140280 · Cited by 364

IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells.

Okada, M., Kitahara, M., Kishimoto, S., Matsuda, T., Hirano, T., & Kishimoto, T. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.141.5.1543 · Cited by 360

Factors Affecting B-Cell Growth and Differentiation

Kishimoto, T. (1985) · Annual Review of Immunology · doi:10.1146/annurev.iy.03.040185.001025 · Cited by 360

Historical overview of the interleukin-6 family cytokine

Kang, S., Narazaki, M., Metwally, H., & Kishimoto, T. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20190347 · Cited by 360

Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock

Pathan, N., Hemingway, C. A., Alizadeh, A. A., Stephens, A. C., Boldrick, J. C., Oragui, E. E., McCabe, C., Welch, S. B., Whitney, A. R., O’Gara, P., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(03)15326-3 · Cited by 358

IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF- and IL-17

Hashizume, M., Hayakawa, N., & Mihara, M. (2008) · Rheumatology · doi:10.1093/rheumatology/ken363 · Cited by 352

Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study)

Nakaoka, Y., Isobe, M., Takei, S., Tanaka, Y., Ishii, T., Yokota, S., Nomura, A., Yoshida, S., & Nishimoto, N. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211878 · Cited by 344

Protective Effects of IL-6 Blockade in Sepsis Are Linked to Reduced C5a Receptor Expression1

Riedemann, N., Neff, T., Guo, R., Bernacki, K. D., Laudes, I. J., Sarma, J., Lambris, J. D., & Ward, P. A. (2003) · Journal of Immunology · doi:10.4049/jimmunol.170.1.503 · Cited by 340

IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome

Kang, S., Tanaka, T., Inoue, H., Ono, C., Hashimoto, S., Kioi, Y., Matsumoto, H., Matsuura, H., Matsubara, T., Shimizu, K., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2010229117 · Cited by 334

Yes-Associated Protein Up-regulates Jagged-1 and Activates the NOTCH Pathway in Human Hepatocellular Carcinoma

Tschaharganeh, D. F., Chen, X., Latzko, P., Malz, M., Gaida, M. M., Felix, K., Ladu, S., Singer, S., Pinna, F., Gretz, N., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.009 · Cited by 326

Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor

Lust, J. A., Donovan, K. A., Kline, M. P., Greipp, P. R., Kyle, R. A., & Maihle, N. J. (1992) · Cytokine · doi:10.1016/1043-4666(92)90043-q · Cited by 316

Late interleukin-6 escalates T follicular helper cell responses and controls a chronic viral infection

Harker, J. A., Lewis, G. M., Mack, L., & Zuniga, E. I. (2011) · Science · doi:10.1126/science.1208421 · Cited by 311

Inflammatory Skin and Bowel Disease Linked toADAM17Deletion

Blaydon, D. C., Biancheri, P., Di, W., Plagnol, V., Cabral, R. M., Brooke, M. A., van Heel, D. A., Rüschendorf, F., Toynbee, M., Walne, A. J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1100721 · Cited by 307

The IκB kinase complex regulates the stability of cytokine-encoding mRNA induced by TLR–IL-1R by controlling degradation of regnase-1

Iwasaki, H., Takeuchi, O., Teraguchi, S., Matsushita, K., Uehata, T., Kuniyoshi, K., Satoh, T., Saitoh, T., Matsushita, M., Standley, D. M., et al. (2011) · Nature Immunology · doi:10.1038/ni.2137 · Cited by 296

Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system

De Benedetti, F., Rucci, N., Del Fattore, A., Peruzzi, B., Paro, R., Longo, M., Vivarelli, M., Muratori, F., Berni, S., Ballanti, P., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22175 · Cited by 296

Genomic structure of the murine IL-6 gene. High degree conservation of potential regulatory sequences between mouse and human.

Tanabe, O., Akira, S., Kamiya, T., Wong, G. G., Hirano, T., & Kishimoto, T. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.141.11.3875 · Cited by 292

Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study

Araki, M., Matsuoka, T., Miyamoto, K., Kusunoki, S., Okamoto, T., Murata, M., Miyake, S., Aranami, T., & Yamamura, T. (2014) · Neurology · doi:10.1212/wnl.0000000000000317 · Cited by 284

Clinical aspects of systemic amyloid diseases

Obici, L. P., Perfetti, V., Palladini, G. O., Moratti, R., & Merlini, G. (2005) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2005.08.014 · Cited by 277

Adult-onset Still disease

Fautrel, B. (2008) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2008.08.006 · Cited by 276

Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study

Biran, N., Ip, A., Ahn, J., Go, R. C., Wang, S., Mathura, S., Sinclaire, B., Bednarz, U., Marafelias, M., Hansen, E., et al. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30277-0 · Cited by 275

Enhanced and coordinated in vivo expression of inflammatory cytokines and nitric oxide synthase by chondrocytes from patients with osteoarthritis

Melchiorri, C., Melicòni, R., Frizziero, L., Silvestri, T., Pulsatelli, L., Mazzetti, I., Borzı̀, R. M., Uguccioni, M., & Facchini, A. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199812)41:12 · Cited by 254

Dysregulated interleukin 6 expression produces a syndrome resembling Castleman’s disease in mice

Brandt, S. J., Bodine, D. M., Dunbar, C. E., & Nienhuis, A. W. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114749 · Cited by 248

The expression of the interleukin 6 gene is induced by the human immunodeficiency virus 1 TAT protein.

Scala, G., Ruocco, M. R., Ambrosino, C., Mallardo, M., Giordano, V., Baldassarre, F., Dragonetti, E., Quinto, I., & Venuta, S. (1994) · The Journal of Experimental Medicine · doi:10.1084/jem.179.3.961 · Cited by 242

Interleukin-6 and RANTES in Takayasu Arteritis

Noris, M., Daina, E., Gamba, S., Bonazzola, S., & Remuzzi, G. (1999) · Circulation · doi:10.1161/01.cir.100.1.55 · Cited by 236

Interleukin-6 Causes Endothelial Barrier Dysfunction via the Protein Kinase C Pathway

Desai, T. R., Leeper, N. J., Hynes, K. L., & Gewertz, B. L. (2002) · Journal of Surgical Research · doi:10.1006/jsre.2002.6415 · Cited by 235

IL-6-regulated transcription factors

Akira, S. (1997) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(97)00063-0 · Cited by 231

The IL-6-Soluble IL-6Rα Autocrine Loop of Endothelial Activation as an Intermediate Between Acute and Chronic Inflammation: an Experimental Model Involving Thrombin

Marin, V., Montero-Julian, F., Grès, S., Boulay, V., Bongrand, P., Farnarier, C., & Kaplanski, G. (2001) · Journal of Immunology · doi:10.4049/jimmunol.167.6.3435 · Cited by 227

Arid5a controls IL-6 mRNA stability, which contributes to elevation of IL-6 level in vivo

Masuda, K., Ripley, B., Nishimura, R., Mino, T., Takeuchi, O., Shioi, G., Kiyonari, H., & Kishimoto, T. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1307419110 · Cited by 226

Anti-interleukin 6 receptor antibody treatment in rheumatic disease

Nishimoto, N., Kishimoto, T., & Yoshizaki, K. (2000) · Annals of the Rheumatic Diseases · doi:10.1136/ard.59.suppl_1.i21 · Cited by 222

Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study

Genovese, M. C., Fleischmann, R., Kivitz, A. J., Rell‐Bakalarska, M., Martincova, R., Fiore, S., Rohane, P., van Hoogstraten, H., Garg, A., Fan, C., et al. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39093 · Cited by 219

A biallelic mutation in IL6ST encoding the GP130 co-receptor causes immunodeficiency and craniosynostosis

Schwerd, T., Twigg, S. R. F., Aschenbrenner, D., Manrique, S., Miller, K. A., Taylor, I. B., Capitani, M., McGowan, S. J., Sweeney, E. A., Weber, A. P., et al. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20161810 · Cited by 209

High serum interleukin‐6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B

Wong, V. W., Yu, J. Q., Cheng, A. S. L., Wong, G. L., Chan, H., Chu, E. S., Ng, E. K. O., Chan, F. K. L., Sung, J. J. �., & Chan, H. L. (2009) · International Journal of Cancer · doi:10.1002/ijc.24281 · Cited by 208

Loss of the interleukin-6 receptor causes immunodeficiency, atopy, and abnormal inflammatory responses

Spencer, S., Bal, S. K., Egner, W., Allen, H. L., Raza, S. I., Ma, C. A., Gürel, M., Zhang, Y., Sun, G., Sabroe, R. A., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20190344 · Cited by 208

Structure‐function analysis of human IL‐6 receptor: dissociation of amino acid residues required for IL‐6‐binding and for IL‐6 signal transduction through gp130.

Yawata, H., Yasukawa, K., Natsuka, S., Murakami, M., Yamasaki, K., Hibi, M., Taga, T., & Kishimoto, T. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05815.x · Cited by 205

MicroRNA-155 Regulates Inflammatory Cytokine Production in Tumor-associated Macrophages via Targeting C/EBPβ

He, M. Y., Xu, Z., Ding, T., Kuang, D., & Zheng, L. (2009) · Cellular and Molecular Immunology · doi:10.1038/cmi.2009.45 · Cited by 200

Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial

Kaneko, Y., Kameda, H., Ikeda, K., Ishii, T., Murakami, K., Takamatsu, H., Tanaka, Y., Abe, T., & Takeuchi, T. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-213920 · Cited by 192

Expression and Function of C5a Receptor in Mouse Microvascular Endothelial Cells

Laudes, I. J., Chu, J. C., Huber-Lang, M. S., Guo, R., Riedemann, N. C., Sarma, J. V., Mahdi, F., Murphy, H. S., Speyer, C. L., Lu, K. T., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.10.5962 · Cited by 181

Therapeutic uses of anti-interleukin-6 receptor antibody

Kang, S., Tanaka, T., & Kishimoto, T. (2014) · International Immunology · doi:10.1093/intimm/dxu081 · Cited by 174

Interleukin-6 in serum of patients with polymyalgia rheumatica and giant cell arteritis

DASGUPTA, B., & PANAYI, G. S. (1990) · Rheumatology · doi:10.1093/rheumatology/29.6.456 · Cited by 171

Hepatic cytochrome P450 down‐regulation during aseptic inflammation in the mouse is interleukin 6 dependent

Siewert, E., Bort, R., Kluge, R., Heinrich, P. C., Castell, J., & Jover, R. (2000) · Hepatology · doi:10.1053/jhep.2000.8532 · Cited by 170

The soluble interleukin 6 receptor: advanced therapeutic options in inflammation

Rose‐John, S. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.782 · Cited by 169

Soluble IL-6 Receptor Potentiates the Antagonistic Activity of Soluble gp130 on IL-6 Responses

Müller‐Newen, G., Küster, A., Hemmann, U., Keul, R., Horsten, U., Martens, A. S., Graeve, L., Wijdenes, J., & Heinrich, P. C. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.11.6347 · Cited by 162

The interleukin-6 receptor Asp358Ala single nucleotide polymorphism rs2228145 confers increased proteolytic conversion rates by ADAM proteases

Garbers, C., Monhasery, N., Aparicio-Siegmund, S., Lokau, J., Baran, P., Nowell, M. A., Jones, S. A., Rose-John, S., & Scheller, J. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.05.018 · Cited by 155

Circulating markers of angiogenesis and endotheliopathy in COVID‐19

Pine, A. B., Meizlish, M. L., Goshua, G., Chang, C., Zhang, H., Bishai, J. D., Bahel, P., Patel, A. J., Gbyli, R., Kwan, J. M., et al. (2020) · Pulmonary Circulation · doi:10.1177/2045894020966547 · Cited by 152

A Novel Mechanism of Neutrophil Recruitment in a Coculture Model of the Rheumatoid Synovium

Lally, F., Smith, E., Filer, A., Stone, M. A., Shaw, J., Nash, G., Buckley, C., & Rainger, G. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21394 · Cited by 142

Aryl hydrocarbon receptor deficiency in T cells suppresses the development of collagen-induced arthritis

Nakahama, T., Kimura, A., Nguyen, N. T., Chinen, I., Hanieh, H., Nohara, K., Fujii‐Kuriyama, Y., & Kishimoto, T. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111786108 · Cited by 136

Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights

Obstfeld, A. E., Frey, N. V., Mansfield, K. G., Lacey, S. F., June, C. H., Porter, D. L., Melenhorst, J. J., & Wasik, M. A. (2017) · Blood · doi:10.1182/blood-2017-08-802413 · Cited by 134

HHV-8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice.

Suthaus, J., Stuhlmann-Laeisz, C., Tompkins, V., Rosean, T. R., Klapper, W., Tosato, G., Janz, S., Scheller, J., & Rose-John, S. (2012) · Blood · doi:10.1182/blood-2011-09-377705 · Cited by 131

Combined interleukin 6 and soluble interleukin 6 receptor accelerates murine liver regeneration

Peters, M., Blinn, G., Jostock, T., Schirmacher, P., Büschenfelde, K. M. Z., Galle, P. R., & Rose–John, S. (2000) · Gastroenterology · doi:10.1053/gast.2000.20236 · Cited by 129

Preclinical In Vivo Modeling of Cytokine Release Syndrome Induced by ErbB-Retargeted Human T Cells: Identifying a Window of Therapeutic Opportunity?

van der Stegen, S. J. C., Davies, D. M., Wilkie, S., Foster, J., Sosabowski, J. K., Burnet, J., Whilding, L. M., Petrovic, R. M., Ghaem-Maghami, S., Mather, S., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301523 · Cited by 126

MiR-26 down-regulates TNF-α/NF-κB signalling and IL-6 expression by silencing HMGA1 and MALT1

Chen, C. A., Chang, J. T., Ho, Y.-F., & Shyu, A. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw205 · Cited by 104

The IL6R variation Asp358Ala is a potential modifier of lung function in subjects with asthma

Hawkins, G. A., Robinson, M., Hastie, A. T., Li, X., Li, H., Moore, W. C., Howard, T. D., Busse, W. W., ERZURUM, S. C., Wenzel, S. E., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.03.018 · Cited by 98

YAP–IL-6ST autoregulatory loop activated on APC loss controls colonic tumorigenesis

Taniguchi, K., Moroishi, T., de Jong, P. R., Krawczyk, M., Grebbin, B. M., Luo, H., Xu, R., Golob‐Schwarzl, N., Schweiger, C., Wang, K., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620290114 · Cited by 96

Gab-Family Adapter Molecules in Signal Transduction of Cytokine and Growth Factor Receptors, and T and B Cell Antigen Receptors

Hibi, M., & Hirano, T. (2000) · Leukemia and Lymphoma · doi:10.3109/10428190009089430 · Cited by 94

Arid5a regulates naive CD4+ T cell fate through selective stabilization of Stat3 mRNA

Masuda, K., Ripley, B., Nyati, K. K., Dubey, P. K., Zaman, M. M.-U., Hanieh, H., Higa, M., Yamashita, K., Standley, D. M., Mashima, T., et al. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20151289 · Cited by 88

Regulation of Antibody Response in Vitro

Kishimoto, T., & Ishizaka, K. (1973) · The Journal of Immunology · doi:10.4049/jimmunol.111.4.1194 · Cited by 83

Catch‐Up Growth During Tocilizumab Therapy for Systemic Juvenile Idiopathic Arthritis: Results From a Phase III Trial

Benedetti, F. D., Brunner, H. I., Ruperto, N., Schneider, R., Xavier, R. M., Allen, R. C., Brown, D. E., Chaitow, J., Pardeo, M., Espada, G., et al. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38984 · Cited by 81

In Vitro Immune Response of Human Peripheral Lymphocytes

Hirano, T., Kuritani, T., Kishimoto, T., & Yamamura, Y. (1977) · The Journal of Immunology · doi:10.4049/jimmunol.119.4.1235 · Cited by 76

Soluble gp130 prevents interleukin-6 and interleukin-11 cluster signaling but not intracellular autocrine responses

Lamertz, L., Rummel, F., Polz, R., Baran, P., Hansen, S., Waetzig, G. H., Moll, J. M., Floss, D. M., & Scheller, J. (2018) · Science Signaling · doi:10.1126/scisignal.aar7388 · Cited by 70

Modification of the anti‐CD3‐induced cytokine release syndrome by anti‐interferon‐γ or anti‐interleukin‐6 antibody treatment: Protective effects and biphasic changes in blood cytokine levels

Matthys, P., Dillen, C., Proost, P., Heremans, H., Damme, J. V., & Billiau, A. (1993) · European Journal of Immunology · doi:10.1002/eji.1830230924 · Cited by 69

Post-transcriptional regulation of immune responses by RNA binding proteins

Mino, T., & Takeuchi, O. (2018) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.94.017 · Cited by 68

Regulation of Antibody Response in Vitro

Kishimoto, T., & Ishizaka, K. (1973) · The Journal of Immunology · doi:10.4049/jimmunol.111.3.720 · Cited by 67

Association of interleukin-6 gene polymorphism with coronary artery disease: an updated systematic review and cumulative meta-analysis

Hou, H., Wang, C., Sun, F., Zhao, L., Dun, A., & Sun, Z. (2015) · Inflammation Research · doi:10.1007/s00011-015-0850-9 · Cited by 55

Regulation of the Interleukin-6 gene expression during monocytic differentiation of HL-60 cells by chromatin remodeling and methylation

Poplutz, M. K., Weßels, I., Rink, L., & Uciechowski, P. (2014) · Immunobiology · doi:10.1016/j.imbio.2014.03.016 · Cited by 52

The IL-6-neutralizing sIL-6R/sgp130 buffer system is disturbed in patients with type 2 diabetes.

Aparicio-Siegmund, S., Garbers, Y., Flynn, C. M., Waetzig, G. H., Gouni-Berthold, I., Krone, W., Berthold, H., Laudes, M., Rose-John, S., & Garbers, C. (2019) · American Journal of Physiology. Endocrinology and Metabolism · doi:10.1152/ajpendo.00166.2019 · Cited by 45

The advanced glycation end product pentosidine correlates to IL-6 and other relevant inflammatory markers in rheumatoid arthritis

Hein, G. E., Köhler, M. M., Oelzner, P., Stein, G., & Franke, S. (2004) · Rheumatology International · doi:10.1007/s00296-004-0518-1 · Cited by 45

AT‐Rich–Interactive Domain–Containing Protein 5A Functions as a Negative Regulator of Retinoic Acid Receptor–Related Orphan Nuclear Receptor γt–Induced Th17 Cell Differentiation

Saito, Y., Kagami, S., Sanayama, Y., Ikeda, K., Suto, A., Kashiwakuma, D., Furuta, S., Iwamoto, I., Nonaka, K., Ohara, O., et al. (2013) · Arthritis & Rheumatology · doi:10.1002/art.38324 · Cited by 40

CD40 promotion of amyloid beta production occurs via the NF‐κB pathway

Ait‐Ghezala, G., Volmar, C., Frieling, J. S., Paris, D., Tweed, M., Bakshi, P., & MULLAN, M. J. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05424.x · Cited by 24

Regulation of Antibody Response in Vitro

Kishimoto, T., & Ishizaka, K. (1973) · The Journal of Immunology · doi:10.4049/jimmunol.111.1.1 · Cited by 24

Effect of Tocilizumab on growth impairment in systemic juvenile idiopathic arthritis with long-term corticosteroid therapy

Miyamae, T., Yokoya, S., Yamanaka, H., & Yokota, S. (2013) · Modern Rheumatology · doi:10.3109/14397595.2013.844404 · Cited by 14

Inotropic Effects of Calcium Antagonists in the Cardiomyopathic Syrian Hamster

Finkel, M. S., Romeo, R. C., Oddis, C. V., & Salama, G. (1992) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199204000-00011 · Cited by 14

Targeting IL-6 trans-signalling: past, present and future prospects

Rose-John, S., Jenkins, B. J., Garbers, C., Moll, J. M., & Scheller, J. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00856-y · Cited by 524

Targeting cytokine and chemokine signaling pathways for cancer therapy

Yi, M., Li, T., Niu, M., Zhang, H., Wu, Y., Wu, K., & Dai, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01868-3 · Cited by 528

Interleukin-6 cytokine: An overview of the immune regulation, immune dysregulation, and therapeutic approach

Aliyu, M., Zohora, F. T., Anka, A. U., Ali, K., Maleknia, S., Saffarioun, M., & Azizi, G. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109130 · Cited by 455

The advent of immune stimulating CAFs in cancer

Tsoumakidou, M. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00549-7 · Cited by 192

Hemophagocytic lymphohistiocytosis: current treatment advances, emerging targeted therapy and underlying mechanisms

Wu, Y., Sun, X., Kang, K., Yang, Y., Li, H., Zhao, A., & Niu, T. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01621-x · Cited by 115

IL-6: from arthritis to CAR-T-cell therapy and COVID-19

Kishimoto, T. (2021) · International Immunology · doi:10.1093/intimm/dxab011 · Cited by 26

Interleukin (IL-6) ImmunotherapyPreprint

Tanaka, T., Narazaki, M., & Kishimoto, T. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028456 · Cited by 419

Pathogenetic significance of the use of a humanized monoclonal antibody to the IL-6-α receptor (tocilizumab) in the treatment of immuno-inflammatory diseases

Vi, M., Belyaeva, I. B., Samigullina, R. R., Леонидович, Ч. А., & Dadalova, A. M. (2020) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2020-8-102-112 · Cited by 1

Interleukin-6 inhibitors: from the therapy of immuno-inflammatory rheumatic diseases to use in COVID-19

Muravyeva, N., & Belov, B. (2022) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2022-16-11-88-94

Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms

Kang, S., & Kishimoto, T. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00649-0 · Cited by 399